Cargando…
A glycan gate controls opening of the SARS-CoV-2 spike protein
SARS-CoV-2 infection is controlled by the opening of the spike protein receptor binding domain (RBD), which transitions from a glycan-shielded “down” to an exposed “up” state in order to bind the human ACE2 receptor and infect cells. While snapshots of the “up” and “down” states have been obtained b...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488004/ https://www.ncbi.nlm.nih.gov/pubmed/34413500 http://dx.doi.org/10.1038/s41557-021-00758-3 |
_version_ | 1784578060675186688 |
---|---|
author | Sztain, Terra Ahn, Surl-Hee Bogetti, Anthony T. Casalino, Lorenzo Goldsmith, Jory A. Seitz, Evan McCool, Ryan S. Kearns, Fiona L. Acosta-Reyes, Francisco Maji, Suvrajit Mashayekhi, Ghoncheh McCammon, J. Andrew Ourmazd, Abbas Frank, Joachim McLellan, Jason S. Chong, Lillian T. Amaro, Rommie E. |
author_facet | Sztain, Terra Ahn, Surl-Hee Bogetti, Anthony T. Casalino, Lorenzo Goldsmith, Jory A. Seitz, Evan McCool, Ryan S. Kearns, Fiona L. Acosta-Reyes, Francisco Maji, Suvrajit Mashayekhi, Ghoncheh McCammon, J. Andrew Ourmazd, Abbas Frank, Joachim McLellan, Jason S. Chong, Lillian T. Amaro, Rommie E. |
author_sort | Sztain, Terra |
collection | PubMed |
description | SARS-CoV-2 infection is controlled by the opening of the spike protein receptor binding domain (RBD), which transitions from a glycan-shielded “down” to an exposed “up” state in order to bind the human ACE2 receptor and infect cells. While snapshots of the “up” and “down” states have been obtained by cryoEM and cryoET, details of the RBD opening transition evade experimental characterization. Here, over 130 μs of weighted ensemble (WE) simulations of the fully glycosylated spike ectodomain allow us to characterize more than 300 continuous, kinetically unbiased RBD opening pathways. Together with ManifoldEM analysis of cryo-EM data and biolayer interferometry experiments, we reveal a gating role for the N-glycan at position N343, which facilitates RBD opening. Residues D405, R408, and D427 also participate. The atomic-level characterization of the glycosylated spike activation mechanism provided herein achieves a new high-water mark for ensemble pathway simulations and offers a foundation for understanding the fundamental mechanisms of SARS-CoV-2 viral entry and infection. |
format | Online Article Text |
id | pubmed-8488004 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
record_format | MEDLINE/PubMed |
spelling | pubmed-84880042022-02-19 A glycan gate controls opening of the SARS-CoV-2 spike protein Sztain, Terra Ahn, Surl-Hee Bogetti, Anthony T. Casalino, Lorenzo Goldsmith, Jory A. Seitz, Evan McCool, Ryan S. Kearns, Fiona L. Acosta-Reyes, Francisco Maji, Suvrajit Mashayekhi, Ghoncheh McCammon, J. Andrew Ourmazd, Abbas Frank, Joachim McLellan, Jason S. Chong, Lillian T. Amaro, Rommie E. Nat Chem Article SARS-CoV-2 infection is controlled by the opening of the spike protein receptor binding domain (RBD), which transitions from a glycan-shielded “down” to an exposed “up” state in order to bind the human ACE2 receptor and infect cells. While snapshots of the “up” and “down” states have been obtained by cryoEM and cryoET, details of the RBD opening transition evade experimental characterization. Here, over 130 μs of weighted ensemble (WE) simulations of the fully glycosylated spike ectodomain allow us to characterize more than 300 continuous, kinetically unbiased RBD opening pathways. Together with ManifoldEM analysis of cryo-EM data and biolayer interferometry experiments, we reveal a gating role for the N-glycan at position N343, which facilitates RBD opening. Residues D405, R408, and D427 also participate. The atomic-level characterization of the glycosylated spike activation mechanism provided herein achieves a new high-water mark for ensemble pathway simulations and offers a foundation for understanding the fundamental mechanisms of SARS-CoV-2 viral entry and infection. 2021-08-19 2021-10 /pmc/articles/PMC8488004/ /pubmed/34413500 http://dx.doi.org/10.1038/s41557-021-00758-3 Text en https://www.springernature.com/gp/open-research/policies/accepted-manuscript-termsUsers may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: https://www.springernature.com/gp/open-research/policies/accepted-manuscript-terms |
spellingShingle | Article Sztain, Terra Ahn, Surl-Hee Bogetti, Anthony T. Casalino, Lorenzo Goldsmith, Jory A. Seitz, Evan McCool, Ryan S. Kearns, Fiona L. Acosta-Reyes, Francisco Maji, Suvrajit Mashayekhi, Ghoncheh McCammon, J. Andrew Ourmazd, Abbas Frank, Joachim McLellan, Jason S. Chong, Lillian T. Amaro, Rommie E. A glycan gate controls opening of the SARS-CoV-2 spike protein |
title | A glycan gate controls opening of the SARS-CoV-2 spike protein |
title_full | A glycan gate controls opening of the SARS-CoV-2 spike protein |
title_fullStr | A glycan gate controls opening of the SARS-CoV-2 spike protein |
title_full_unstemmed | A glycan gate controls opening of the SARS-CoV-2 spike protein |
title_short | A glycan gate controls opening of the SARS-CoV-2 spike protein |
title_sort | glycan gate controls opening of the sars-cov-2 spike protein |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488004/ https://www.ncbi.nlm.nih.gov/pubmed/34413500 http://dx.doi.org/10.1038/s41557-021-00758-3 |
work_keys_str_mv | AT sztainterra aglycangatecontrolsopeningofthesarscov2spikeprotein AT ahnsurlhee aglycangatecontrolsopeningofthesarscov2spikeprotein AT bogettianthonyt aglycangatecontrolsopeningofthesarscov2spikeprotein AT casalinolorenzo aglycangatecontrolsopeningofthesarscov2spikeprotein AT goldsmithjorya aglycangatecontrolsopeningofthesarscov2spikeprotein AT seitzevan aglycangatecontrolsopeningofthesarscov2spikeprotein AT mccoolryans aglycangatecontrolsopeningofthesarscov2spikeprotein AT kearnsfional aglycangatecontrolsopeningofthesarscov2spikeprotein AT acostareyesfrancisco aglycangatecontrolsopeningofthesarscov2spikeprotein AT majisuvrajit aglycangatecontrolsopeningofthesarscov2spikeprotein AT mashayekhighoncheh aglycangatecontrolsopeningofthesarscov2spikeprotein AT mccammonjandrew aglycangatecontrolsopeningofthesarscov2spikeprotein AT ourmazdabbas aglycangatecontrolsopeningofthesarscov2spikeprotein AT frankjoachim aglycangatecontrolsopeningofthesarscov2spikeprotein AT mclellanjasons aglycangatecontrolsopeningofthesarscov2spikeprotein AT chonglilliant aglycangatecontrolsopeningofthesarscov2spikeprotein AT amarorommiee aglycangatecontrolsopeningofthesarscov2spikeprotein AT sztainterra glycangatecontrolsopeningofthesarscov2spikeprotein AT ahnsurlhee glycangatecontrolsopeningofthesarscov2spikeprotein AT bogettianthonyt glycangatecontrolsopeningofthesarscov2spikeprotein AT casalinolorenzo glycangatecontrolsopeningofthesarscov2spikeprotein AT goldsmithjorya glycangatecontrolsopeningofthesarscov2spikeprotein AT seitzevan glycangatecontrolsopeningofthesarscov2spikeprotein AT mccoolryans glycangatecontrolsopeningofthesarscov2spikeprotein AT kearnsfional glycangatecontrolsopeningofthesarscov2spikeprotein AT acostareyesfrancisco glycangatecontrolsopeningofthesarscov2spikeprotein AT majisuvrajit glycangatecontrolsopeningofthesarscov2spikeprotein AT mashayekhighoncheh glycangatecontrolsopeningofthesarscov2spikeprotein AT mccammonjandrew glycangatecontrolsopeningofthesarscov2spikeprotein AT ourmazdabbas glycangatecontrolsopeningofthesarscov2spikeprotein AT frankjoachim glycangatecontrolsopeningofthesarscov2spikeprotein AT mclellanjasons glycangatecontrolsopeningofthesarscov2spikeprotein AT chonglilliant glycangatecontrolsopeningofthesarscov2spikeprotein AT amarorommiee glycangatecontrolsopeningofthesarscov2spikeprotein |